{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:32:13Z","timestamp":1769610733831,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,3,22]],"date-time":"2015-03-22T00:00:00Z","timestamp":1426982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,3,22]],"date-time":"2015-03-22T00:00:00Z","timestamp":1426982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>We investigated how many patients, who presented with Raynaud\u2019s phenomenon (RP) and who had not been classified as systemic sclerosis (SSc), would be reclassified as SSc, if the 2013 American College of Rheumatology (ACR)\/the European League Against Rheumatism (EULAR) classification criteria were used. We also analyzed the predictive values of the reclassification as SSc in those patients.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>We consecutively enrolled 64 patients with RP and 60 patients with SSc. We applied the new classification criteria to them, reclassified them, and compared variables between those who were newly classified as SSc and those who were not or previously classified as SSc.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Seventeen of 64 patients (26.5%), who presented with RP, but did not fulfill the 1980 ACR classification criteria, were newly classified as SSc by the 2013 ACR\/EULAR classification criteria. The newly classified patients as SSc showed increased frequencies of sclerodactyly, digital tip ulcer, telangiectasia, abnormal nailfold capillaries and the presence of anti-centromere antibody, compared to those not and telangiectasia and anti-centromere antibody, compared to the previously classified patients. For the reclassification as SSc, the variables with independent predictive value were sclerodactyly (odds ratio (OR) 60.025), telangiectasia (OR 13.353) and the presence of anti-centromere antibody (OR 11.168).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Overall, 26.5% of the patients, who presented with RP, but who did not fulfill the 1980 ACR classification criteria, were newly classified as SSc according to the 2013 ACR\/EULAR classification criteria. Sclerodactyly, telangiectasia, and the presence of anti-centromere antibody had independent predictive value for reclassifying patients with RP as SSc.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/s13075-015-0594-5","type":"journal-article","created":{"date-parts":[[2015,3,17]],"date-time":"2015-03-17T19:13:51Z","timestamp":1426619631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Application of the 2013 ACR\/EULAR classification criteria for systemic sclerosis to patients with Raynaud\u2019s phenomenon"],"prefix":"10.1186","volume":"17","author":[{"given":"Jin-Su","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Chan","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason Jungsik","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Kon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,22]]},"reference":[{"key":"594_CR1","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/S0140-6736(00)05118-7","volume":"357","author":"JA Block","year":"2001","unstructured":"Block JA, Sequeira W. Raynaud's phenomenon. Lancet. 2001;357:2042\u20138.","journal-title":"Lancet"},{"key":"594_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2165\/00003495-200767040-00003","volume":"67","author":"JE Pope","year":"2007","unstructured":"Pope JE. The diagnosis and treatment of Raynaud's phenomenon: a practical approach. Drugs. 2007;67:517\u201325.","journal-title":"Drugs"},{"key":"594_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/00002281-199511000-00011","volume":"7","author":"MB Kahaleh","year":"1995","unstructured":"Kahaleh MB. Raynaud\u2019s phenomenon and the vascular disease in scleroderma. Curr Opin Rheumatol. 1995;7:529\u201334.","journal-title":"Curr Opin Rheumatol"},{"key":"594_CR4","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1002\/art.24038","volume":"58","author":"M Koenig","year":"2008","unstructured":"Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to SSc: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58:3902\u201312.","journal-title":"Arthritis Rheum"},{"key":"594_CR5","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1002\/art.27543","volume":"62","author":"AL Herrick","year":"2010","unstructured":"Herrick AL, Cutolo M. Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum. 2010;62:2595\u2013604.","journal-title":"Arthritis Rheum"},{"key":"594_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.semarthrit.2010.08.004","volume":"41","author":"S Chatterjee","year":"2011","unstructured":"Chatterjee S. Pulmonary hypertension in systemic sclerosis. Semin Arthritis Rheum. 2011;41:19\u201337.","journal-title":"Semin Arthritis Rheum"},{"key":"594_CR7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","volume":"380","author":"A Fischer","year":"2012","unstructured":"Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380:689\u201398.","journal-title":"Lancet"},{"issue":"Suppl 3","key":"594_CR8","first-page":"iii36","volume":"48","author":"A Forbes","year":"2009","unstructured":"Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford). 2009;48 Suppl 3:iii36\u201339.","journal-title":"Rheumatology (Oxford)"},{"key":"594_CR9","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/keh671","volume":"44","author":"FA Wollheim","year":"2005","unstructured":"Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford). 2005;44:1212\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"594_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Preliminary criteria for the classification of systemic sclerosis (scleroderma)","year":"1980","unstructured":"Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581\u201390.","journal-title":"Arthritis Rheum"},{"key":"594_CR11","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747\u201355.","journal-title":"Ann Rheum Dis"},{"key":"594_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61:554\u201358.","journal-title":"Ann Rheum Dis"},{"key":"594_CR13","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.","journal-title":"Arthritis Rheum"},{"key":"594_CR14","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/B978-1-4160-3285-4.10079-8","volume-title":"Textbook of Rheumatology","author":"RM Bennett","year":"2009","unstructured":"Bennett RM. Overlap Syndromes. In: Textbook of Rheumatology. 8th ed. Philadelphia: WB Saunders Co; 2009. p. 1381.","edition":"8"},{"key":"594_CR15","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u201388.","journal-title":"Ann Rheum Dis"},{"key":"594_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344\u20137.","journal-title":"N Engl J Med"},{"key":"594_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","volume":"46","author":"SI Nihtyanova","year":"2007","unstructured":"Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2013a retrospective analysis. Rheumatology (Oxford). 2007;46:442\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"594_CR18","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10067-014-2579-1","volume":"33","author":"CG Khor","year":"2014","unstructured":"Khor CG, Chen XL, Lin TS, Lu CH, Hsieh SC. Rituximab for refractory digital infarcts and ulcers in systemic sclerosis. Clin Rheumatol. 2014;33:1019\u201320.","journal-title":"Clin Rheumatol"},{"key":"594_CR19","doi-asserted-by":"crossref","unstructured":"Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2014 [Epub ahead of print].","DOI":"10.1136\/annrheumdis-2013-204522"},{"key":"594_CR20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1136\/annrheumdis-2012-202295","volume":"72","author":"M Matucci-Cerinic","year":"2013","unstructured":"Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S. Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis. Ann Rheum Dis. 2013;72:319\u201321.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0594-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-015-0594-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0594-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0594-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T16:34:15Z","timestamp":1728923655000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-015-0594-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,22]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0594-5","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,22]]},"assertion":[{"value":"19 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"77"}}